Bob Langer's first port of call — Polaris Partners — maps $400M for ninth fund
Health and tech venture group Polaris Partners, which counts Alector, Alnylam and Editas Medicine as part of its portfolio, is setting up its ninth fund, roughly two years after it closed Polaris VIII with $435 million in the bank, surpassing its target by $35 million.
The Boston-based firm, in an SEC filing, said it intends to raise $400 million for the fund. Polaris — which routinely backs companies molded out of the work done in the lab of prolific scientist Bob Langer of MIT — typically invests early, and sticks around till companies are in the green. Like its peers at Flagship and Third Rock, Polaris is all about championing the local biotech scene with a steady flow of startup cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
